Home > Oncology > ASCO 2020 > Lung Cancer > Adjuvant osimertinib in NSCLC: practice changing ADAURA trial

Adjuvant osimertinib in NSCLC: practice changing ADAURA trial

Adjuvant osimertinib demonstrated a statistically significant and clinically meaningful benefit for patients with stage IB, II, or IIIA *EGFR*-mutant non-small cell lung cancer (NSCLC) with complete tumour resection in the phase 3 ADAURA trial, presented by Prof. Roy Herbst (Yale Cancer Center, USA) [1].

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with demonstrated efficacy as a frontline agent for metastatic NSCLC with confirmed *EGFR* mutation [2]. The phase 3 ADAURA clinical trial attempted to assess whether this agent is also effective in earlier stages of metastatic disease characterised by *EGFR* mutation, namely as an adjuvant therapy after complete surgical resection of stage IB, II, or IIIA disease.

Oral osimertinib (80 mg once daily) was compared with placebo for a treatment duration of up to 3 years or until disease r...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on